Abstract
Revascularization remains the cornerstone of managing obstructive coronary artery disease. Although percutaneous coronary interventions involving the insertion of metal scaffolds, known as stents, has emerged as the preferred method of restoring vessel patency, as many as 30% of patients will experience a gradual re-narrowing of the lumen caused by neointima (NI) formation, resulting in a condition known as in-stent restenosis (ISR). ISR represents a significant limitation to percutaneous revascularization – however, abrogating NI formation following stent implantation has been hampered by an incomplete understanding of the pathogenesis of in-stent lesions. While numerous mechanisms have been proposed to explain the pathogenesis of ISR, data from human and animal models have yielded conflicting results. Herein, we review key studies of NI development following vascular injury with a focus on the origin of cells participating in NI formation.
Keywords: In-stent restenosis, neointima, smooth muscle cell, endothelial cell, vascular progenitor cell, endothelial progenitor cell, drug-eluting stents, hyperplasia, contractile phenotype
Cardiovascular & Hematological Disorders-Drug Targets
Title: Pathogenesis of Neointima Formation Following Vascular Injury
Volume: 11 Issue: 1
Author(s): Ali Pourdjabbar, Benjamin Hibbert, Trevor Simard and Xiaoli Ma
Affiliation:
Keywords: In-stent restenosis, neointima, smooth muscle cell, endothelial cell, vascular progenitor cell, endothelial progenitor cell, drug-eluting stents, hyperplasia, contractile phenotype
Abstract: Revascularization remains the cornerstone of managing obstructive coronary artery disease. Although percutaneous coronary interventions involving the insertion of metal scaffolds, known as stents, has emerged as the preferred method of restoring vessel patency, as many as 30% of patients will experience a gradual re-narrowing of the lumen caused by neointima (NI) formation, resulting in a condition known as in-stent restenosis (ISR). ISR represents a significant limitation to percutaneous revascularization – however, abrogating NI formation following stent implantation has been hampered by an incomplete understanding of the pathogenesis of in-stent lesions. While numerous mechanisms have been proposed to explain the pathogenesis of ISR, data from human and animal models have yielded conflicting results. Herein, we review key studies of NI development following vascular injury with a focus on the origin of cells participating in NI formation.
Export Options
About this article
Cite this article as:
Pourdjabbar Ali, Hibbert Benjamin, Simard Trevor and Ma Xiaoli, Pathogenesis of Neointima Formation Following Vascular Injury, Cardiovascular & Hematological Disorders-Drug Targets 2011; 11 (1) . https://dx.doi.org/10.2174/187152911795945169
DOI https://dx.doi.org/10.2174/187152911795945169 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synergistic Two-Way Interactions of Dietary Polyphenols and Dietary Components on the Gut Microbial Composition: Is There a Positive, Negative, or Neutralizing Effect in the Prevention and Management of Metabolic Diseases?
Current Protein & Peptide Science Current Drug Targets and Future Therapy of Pulmonary Arterial Hypertension
Current Medicinal Chemistry LDL and HDL Subfractions, Dysfunctional HDL: Treatment Options
Current Pharmaceutical Design A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes
Current Pharmaceutical Design Chronic Hepatitis C, Insulin Resistance and Vascular Disease
Current Pharmaceutical Design Morbidity and Mortality Associated with Pharmacotherapy. Evolution and Current Concept of Drug-Related Problems
Current Pharmaceutical Design Whole Milk and Full-Fat Dairy Products and Hypertensive Risks
Current Hypertension Reviews Infection-Associated Biomarkers of Inflammation in Atherosclerosis
Current Pharmaceutical Design PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDLCholesterol
Mini-Reviews in Medicinal Chemistry Physical Activity and Diabetic Cardiomyopathy: Myocardial Adaptation Depending on Exercise Load
Current Diabetes Reviews Newer Insights in Personalized and Evidence Based Medicine- the Role of MicroRNAs
Current Pharmacogenomics and Personalized Medicine Mechanisms of Neutrophil-mediated Disease: Innovative Therapeutic Interventions
Current Pharmaceutical Design Protein Oxidative Modification in the Aging Organism and the Role of the Ubiquitin Proteasomal System
Current Pharmaceutical Design Vasopressin Receptor Antagonists in Heart Failure
Recent Patents on Cardiovascular Drug Discovery Multiple Roles of Fibroblast Growth Factor 21 in Metabolism
Current Pharmaceutical Design Hypoxia Inducible Factor 1 as a Therapeutic Target in Ischemic Stroke
Current Medicinal Chemistry Mediterranean Diet and Dementia of the Alzheimer Type
Current Aging Science New Approaches in the Diagnosis of Atherosclerosis and Treatment of Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery COX-2 Inhibitors and Cardiovascular Events: Deja Vu Du Jour
Vascular Disease Prevention (Discontinued) PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders?
Current Pharmaceutical Design